CeriBell, Inc. (NASDAQ:CBLL) Director Sells $131,255.35 in Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 7,445 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $17.63, for a total value of $131,255.35. Following the sale, the director now directly owns 21,230 shares in the company, valued at approximately $374,284.90. This trade represents a 25.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

CeriBell Trading Up 3.2%

Shares of CBLL traded up $0.58 during mid-day trading on Monday, hitting $18.49. 318,510 shares of the company were exchanged, compared to its average volume of 282,407. The company has a quick ratio of 16.81, a current ratio of 17.36 and a debt-to-equity ratio of 0.11. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $32.75. The company has a 50 day moving average of $16.67 and a 200-day moving average of $20.64.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. Equities analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CBLL. Rhumbline Advisers lifted its position in CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock worth $300,000 after buying an additional 3,276 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of CeriBell during the 1st quarter valued at about $175,000. Lord Abbett & CO. LLC grew its holdings in shares of CeriBell by 7.9% in the first quarter. Lord Abbett & CO. LLC now owns 319,501 shares of the company's stock valued at $6,138,000 after purchasing an additional 23,451 shares during the period. Nuveen LLC acquired a new stake in CeriBell during the first quarter worth about $311,000. Finally, Swiss National Bank purchased a new position in CeriBell during the first quarter worth about $467,000.

Wall Street Analysts Forecast Growth

CBLL has been the topic of a number of analyst reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has an average rating of "Buy" and an average price target of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.